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Abstract
A simultaneous stability-indicating HPLC method for the determination of cisapride, methylparaben and propylparaben
in oral suspensions has been developed and validated. Baseline separation was achieved on a C18 column at room tempera-
ture (25°C) by gradient elution with mobile phase consisting of solvent A: 10% v/v acetonitrile in 0.13% w/v sodium-1-
pentanesulfonate pH 8 and solvent B: acetonitrile. The gradient program was as follows: 0-5 min: 20 to 56% solvent B; 5-7
min: 56 to 85% solvent B; 7-10 min: 85% solvent B. The flow rate of mobile phase was 1.2 mL/min. The injection volume was
20 L. Detection and peak purity assessments were performed by photo-diode array detector set at 275 nm with scan mode
in the range of 190-400 nm. The method was selective, accurate and precise. It provided chromatograms with good peak shape
and acceptable resolutions of greater than 4.4 for all analytes including the degradation products formed in oral suspensions
in about 8.5 min.  All analyte peaks were pure. The accuracy of all analytes was in the range of 99.20-100.6%. The within-run
and between-run relative standard deviations were less than 1.50%. The calibration curves for cisapride, methylparaben, and
propylparaben were linear over the concentration range of 10.0-75.0 g/mL, 8.0-100.0 g/mL, and 0.8-10.0 g/mL, respect-
ively with r
2 greater than 0.999. This developed method was successfully applied to the stability study of cisapride, methyl-
paraben and propylparaben in oral suspension formulations.
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1. Introduction
Cisapride (CIS), (±)cis-4-amino-5-chloro-N-[1-[3-(4-
fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-
benzamide (Figure 1; Merck Index, 1996) is a gastrointestinal
prokinetic  agent.  It  is  effective  in  the  treatment  of  gastro-
esophageal reflux disease and non-ulcer dyspepsia in adults,
children and neonates (Reynolds and Putman, 1992; Geldof
et al., 1993; Wiseman and Faulds, 1994; Onat et al., 1994;
Barone et al., 1994; Sweetman, 2005). CIS has been assoc-
iated  with  rare,  but  serious  cardiac  side  effects  including
prolongation of QT interval, torsades de pointes and sudden
cardiac death, especially when concomitantly administered
with CYP450 3A4 inhibitors or in patients with risk factors of
cardiac disorders (Bedford and Rowbotham, 1996; Thomas
et al., 1998; Van Haarst et al., 1998; Wysowski et al., 2001).
However, it does not affect psychomotor function or induce
central  depressant  adverse  effect  as  compared  to  other
prokinetic agents such as metoclopramide and domperidone
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(McCallum et al., 1988). This medicine, therefore, has been
withdrawn in some countries, or its use and indications have
been restricted in some countries (World Health Organiza-
tion, 2001; World Health Organization, 2003).  In Thailand,
CIS has been severely restricted for prescription use by gas-
trointestinal physicians and limited use in gastroesophageal
reflux  disease  patients  only  (World  Health  Organization,
2003)
An oral suspension of CIS has been developed from
cisapride tablets in order to aid patients with difficulty in
swallowing tablets, to allow a more convenient way of adjust-
ing dose for pediatric patients, and to facilitate the adminis-
tration of the drug via the nasogastric tube. This formulation
is preserved with a combination of methylparaben (MP) and
propylparaben (PP), the widely used preservative system in
liquid  formulations.  In  our  study,  hydroxypropyl--cyclo-
dextrin (HP--CD) is added into the formulation to increase
the stability of CIS.
The preservative system is an important part of liquid
formulations in preventing the deterioration of formulations
from microbial contamination. To establish their effectiveness
throughout the shelf life of the product, the actual concen-
trations of preservatives must be determined, as also required
by regulatory agencies. Stability-indicating methods have
been  reported  for  the  determination  of  MP,  PP  and  other
drugs by HPLC (Kollmorgen and Kraut, 1998; Beasley et al.,
2005; Ali et al., 2006; Grosa et al., 2006). A limited number of
stability-indicating HPLC methods have been reported for
the determination of CIS in pharmaceutical preparations
(Nahata et al., 1995; Allen Jr. and Erickson III, 1998; Argekar
and Sawant, 1999). Belgaied and Trabelsi (2003) postulated
that  CIS  is  easily  oxidized  to  give  cisapride  N-oxide,  and
developed a HPLC method for simultaneous determination
of CIS, cisapride N-oxide, PP and butylparaben in suspen-
sion. However, in our study, other degradation products of
CIS  have  been  found.  As  per  bibliographical  revision,  no
analytical methods for simultaneous determination of CIS,
MP and PP that account for the presence of these other de-
gradation products of CIS and p-hydroxybenzoic acid, a
known degradation product of parabens, have been reported.
The aims of this study were to develop and validate a stabil-
ity-indicating HPLC method for simultaneous determination
of  CIS,  MP  and  PP  in  oral  suspension  in  the  presence  of
degradation products of CIS and p-hydroxybenzoic acid for
use in the stability study of CIS, MP and PP in oral suspen-
sion.
2. Material and Methods
2.1 Chemicals
Cisapride (CIS), hydroxypropyl--cyclodextrin (HP--
CD, average MW 1460, molar substitution 0.8), methylpara-
ben  (MP)  and  propylparaben  (PP)  were  purchased  from
Sigma-Aldrich (MO, USA). Acetonitrile, methanol, hydrochlo-
ric acid and sodium hydroxide were obtained from Labscan
Co., Ltd. (Bangkok, Thailand). p-Hydroxybenzoic acid and
sodium-1-pentanesulfonate were purchased from Fluka
(Buchs, Switzerland). Water was obtained using a Milli-Q
water  purification  system  (Millipore  Co.,  MA,  USA).  All
chemicals  were  analytical  or  HPLC  grade,  and  were  used
without further purification.
2.2 Samples
A 1 mg/mL CIS oral suspension was prepared from the
powder of 5-mg CIS tablets (CIPASID
®, Siam Pharmaceutical
Co., Ltd., Bangkok, Thailand) according to the formulation
published by Niazi (2004) with 3% w/v HP-b-CD added. This
oral suspension contains 0.18% w/v MP and 0.02% w/v PP.
A placebo suspension was prepared in the same manner as
the 1 mg/mL CIS oral suspension using powdered placebo
tablets  without  MP  and  PP  added.  The  1  mg/mL  CIS  oral
suspension was kept at 30°C to allow degradation over a
period of 12.5 months.
2.3 Equipments and chromatographic conditions
The HPLC system (Agilent 1100 Series, Agilent Tech-
nologies, USA) consisted of a quaternary pump, an auto-
sampler and a photo-diode array detector. The system, data
acquisition and processing were performed through Chem-
station software. The separation was performed on a C18
column (4.6 mm x 150 mm, 5 m, BDS C18, Thermo Electron
Corporation,  MA,  USA)  at  room  temperature  (25°C)  by
gradient elution with mobile phase consisting of solvent A,
which was a mixture of 0.13% w/v sodium-1-pentanesulfo-
nate pH 8 and acetonitrile (90:10 v/v) and solvent B, which
was acetonitrile. The flow rate of mobile phase was 1.2 mL/
min. The gradient program was as follows: 0-5 min: 20 to
56% solvent B; 5-7 min: 56 to 85% solvent B; 7-10 min: 85%
solvent B, and re-equilibrated column from 10-13.5 min with
20% solvent B at 2.0 mL/min. The mobile phase was filtered
through a 0.22 m membrane filter and degassed by ultra-
sonication before use. Sample injection volume was 20 L.
The photo-diode array detector was set at 275 nm with refer-
ence in 360 nm with scan mode in the range of 190-400 nm.
Peak purity was assessed from photo-diode array spectral
analysis by the instrument software.
2.4 Preparation of stock and calibration standard solutions
The individual stock standard solutions of CIS, MP,
and PP were prepared in methanol at the concentrations of
250 g/mL, 200 g/mL, and 20 g/mL, respectively. All stock
solutions and calibration standard solutions were freshly pre-
pared on the day of analysis. A series of five concentrations
of standard mixture of CIS, MP and PP were then prepared
by appropriately diluting the respective stock solution with
methanol to give the concentration of CIS, MP, and PP in the
range of 10.0-75.0 g/mL, 8.0-100.0 g/mL, and 0.8-10.0 g/
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2.5 Preparation of analytical sample
Immediately after thorough mixing, a sample of 1.0 mL
suspension was transferred into a 25-mL volumetric flask.
The appropriate amount of methanol was then added. The
mixture was sonicated for 10 min and allowed to cool to room
temperature before adjusting to volume with methanol. The
resulting mixture was centrifuged at 3500 rpm for 5 min and
20 L of the clear supernatant was injected directly onto the
column.
2.6 Method validation
The method was validated according to method vali-
dation category I described in USP30 (2007). The following
validation characteristics were addressed: system suitability,
selectivity, accuracy, precision, linearity and range.
2.6.1  System suitability
System suitability standard solution was prepared by
diluting appropriate volume of respective stock solutions
with methanol to give a mixture of 40.0 g/mL
 CIS, 40.0 g/
mL MP and 4.0 g/mL PP. The system suitability parameters,
i.e., injection repeatability, theoretical plates (N) and tailing
factor (T) were evaluated from six replicate injections of the
system suitability standard solution. The parameters N and
T  were  calculated  according  to  the  formulae  specified  in
USP30 (2007) as follows.
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where tR is the retention time of the analyte, W0.5 is the peak
width at half-height, W0.05 is the peak width at 5% of peak
height, and f is the distance between the perpendicular line
dropped from the peak maximum and the peak front at 5% of
peak height. The injection repeatability was determined from
the  relative  standard  deviation  (RSD)  of  peak  areas  from
replicate injections.
2.6.2  Selectivity
Selectivity of the method was evaluated by comparing
the chromatograms from MP- and PP-free placebo suspen-
sion, freshly prepared CIS suspension, controlled-30°C real
time degraded CIS suspension and standard mixture of CIS,
MP and PP in methanol to investigate any interference from
sample matrix as well as degradation products on the analy-
sis of CIS, MP and PP. The resolution factors between the
analytes  of  interest  and  the  adjacent  resolved  peaks  were
calculated according to USP30 (2007). The selectivity was
also evaluated from peak purity analysis established from
spectral analysis by the instrument software.
2.6.3  Accuracy and precision
Accuracy and precision of the method were determined
from replicate analysis of placebo suspension spiked with
known  amount  of  CIS,  MP  and  PP  at  50,  100  and  120%
labeled amount. The within-run accuracy and precision were
determined from five replicate determinations of samples in a
single analytical run. The between-run accuracy and preci-
sion were determined from five replicate determinations of
five analytical runs performed on five different days (one
batch of sample per day). The accuracy was expressed in term
of % accuracy calculated as the percentage of the estimated
analyte concentration obtained from standard calibration
curve and the known added concentration. The precision of
the method was expressed as RSD of the estimated concen-
trations from replicate determinations.
2.6.4  Linearity and range
Five concentrations of calibration standard solutions
containing the mixture of CIS, MP, and PP, at the concentra-
tion range of 10.0-75.0 g/mL, 8.0-100.0 g/mL, and 0.8-10.0
g/mL, respectively, were analyzed. Linear regression analy-
sis was used to evaluate the linear relationship between peak
area of the analyte (y) and concentration (x).
2.6.5  Solution stability
The system suitability standard solution and analyti-
cal sample solutions were left in the autosampler at ambient
temperature (25°C). These solutions were repetitively injected
every 4 h for 24 h. The percentage change of analyte peak
area at each time point with respect to the initial peak area
(t = 0) was calculated. The RSD of peak area from repeated
injections was also estimated. The analyte is considered stable
if the percentage change of analyte peak area is within 2%
(Green, 1996).
2.7  Application of the developed method
The developed method was applied to the stability
study of CIS, MP and PP in 1 mg/mL CIS oral suspension
with and without 3% w/v HP--CD to investigate the effect of
HP--CD on the stability of these three compounds in oral
suspension. The samples were stored at 5°C and 30°C, and
the amount of CIS, MP and PP were simultaneously deter-
mined by the proposed method at the specified intervals over
a period of about 12.5 months.
3. Results and Discussion
3.1 Method Development and optimization
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cating HPLC method for simultaneous determination of CIS,
MP  and  PP  in  the  presence  of  p-hydroxybenzoic  acid,  a
known degradation product of parabens, and degradation
products from CIS to be used in the stability study of CIS, MP
and PP in oral suspension. Ion-paired reversed phase HPLC
with isocratic elution was initially selected in method devel-
opment, using forced degradation solution of CIS in 1 M
HCl, 1 M NaOH and 3% H2O2. The optimum separation of
CIS,  MP,  PP,  p-hydroxybenzoic  acid  and  degradation
products from CIS was achieved with the mobile phase con-
sisting of 0.1% w/v sodium-1-pentanesulfonate pH 8 and
acetonitrile  (55:45, v/v).  However,  when  this  separation
system was applied for the analysis of samples of 1 mg/mL
CIS oral suspension from the stability study, other degrada-
tion products were found to co-elute with MP and PP, as
evidenced from peak purity analysis. Therefore, gradient
elution was developed, based on the mobile phase consisting
of  10%  v/v  acetonitrile  in  0.13%  w/v  sodium-1-pentane-
sulfonate pH 8 as solvent A and acetonitrile as solvent B.
The addition of 10% v/v acetonitrile into the aqueous part of
mobile phase was to prevent microbial growth during the
analysis of a large number of stability samples. This chro-
matographic  system  provided  chromatograms  with  good
peak shape and acceptable resolution of all analytes in about
8.5 min. Figure 2(B) and 2(C) show typical chromatograms
from the freshly prepared and degraded samples of 1 mg/mL
CIS oral suspension, respectively.
3.2 Method validation
3.2.1  System suitability
The system suitability parameters, N, T and injection
repeatability, from six replicate injections are presented in
Table 1. All parameters met the recommended criteria of the
CDER reviewer guidance on validation of chromatographic
methods (CDER, 1994), i.e., N should be > 2000, T should be
< 2 and RSD of five or more (n > 5) replicate injections should
be < 1%.
3.2.2  Selectivity
Figure 2 illustrates the selectivity of the method. No
interferences from sample matrix and degradation products on
the peak of CIS, MP and PP were observed. Spectral analysis
also indicated that all of these peaks were pure. The chro-
Figure 2. HPLC chromatogram of (A) MP- and PP-free placebo suspension, (B) freshly prepared 1 mg/mL
 CIS suspension, (C) degraded
1 mg/mL
 CIS suspension, and (D) standard mixture of CIS (40.0 g/mL), MP (40.0 g/mL) and PP (4.0 g/mL) in methanol. I,
II, III, IV, and V are CIS degradation product I, II, III, IV, and V, respectively.383 J. Boonleang & C. Tanthana / Songklanakarin J. Sci. Technol. 32 (4), 379-385, 2010
matographic system used in this study can effectively resolve
CIS, MP, PP and degradation products with baseline separa-
tion. The retention times of MP, PP, and CIS were approxi-
mately 3.6, 5.6, and 7.2 min, respectively. Peak at retention
time about 1.8 min was identified as p-hydroxybenzoic acid
based on the retention data and UV-spectrum obtained by
injecting p-hydroxybenzoic acid-spiked authentic sample.
Peaks at retention time of 1.2, 4.3, 4.7, 4.9, and 8.2 min were
from CIS degradation product I, II, III, IV, and V, respectively.
The CIS degradation product I and V were the same as those
obtained from acid hydrolysis of CIS in 0.1 N HCl, whereas
CIS degradation product II, III and IV were formed in the
suspension during storage at 30°C. The resolution factors of
five critical pairs, namely, p-hydroxybenzoic acid-MP, MP-
CIS  degradation  products  II,  CIS  degradation  products
IV-PP, PP-CIS, and CIS-CIS degradation products V were
13.08, 5.12, 4.44, 10.96, and 7.52, respectively.
3.2.3  Accuracy and precision
The within- and between-run accuracy and precision
are shown in Table 2. The developed method was very accu-
rate and precise. The within- and between-run accuracy for
the determination of CIS, MP and PP were within 98.0-102.0%.
The within- and between-run precision of the method, as
determined from RSD, were less than 2% for all analytes.
3.2.4  Linearity and range
The linear relationship between peak area (y) and
analyte concentration (x) of CIS, MP, and PP over the five
studied concentrations ranged from 10.0-75.0 g/mL, 8.0-
100.0 g/mL, and 0.8-10.0 g/mL, respectively, was establish-
ed. These concentration ranges covered the concentration
range of 50-120% labeled amount of CIS, MP and PP in oral
suspension  at  which  the  method  has  been  validated  to
provide acceptable accuracy and precision. The equations for
mean of five calibration curves of each analyte from linear
regression were: CIS; y = 33.5958x – 21.1420 (r
2 = 0.9998), MP;
y = 42.3487x + 9.7861 (r
2 = 0.9998), and PP; y = 36.7967x +
1.9250 (r
2 = 0.9997). That the coefficient of determination (r
2)
of calibration curve for all analytes was greater than 0.999
indicated the excellent fit of the regression line.
3.2.5  Solution stability
The results of solution stability are shown in Table 3.
CIS, MP and PP in standard solution, as well as in sample
Table 1. System suitability parameters
           Parameters CIS MP PP
Theoretical plates (N)
a 45798 (2.37) 7206 (1.75) 22895 (2.29)
Tailing  factor (T)
a 1.08 (1.47) 0.92 (1.07) 0.94 (0.64)
Injection repeatability
a
   Peak area 1256.86 (0.34) 1939.59 (0.60) 184.74 (0.65)
   Retention time 7.242 (0.23) 3.600 (0.43) 5.600 (0.34)
a Expressed as mean from six replicate injections of system suitability
  standard solution with RSD (%) in the parentheses.
Table 2. Accuracy and precision for the simultaneous determination of CIS, MP and PP in
oral suspension (n = 5)
       Accuracy (%)      Precision (RSD, %)
Analytes
Within-run Between-run Within-run Between-run
CIS 50 99.93 99.95 1.21 1.25
100 99.68 99.20 1.11 0.44
120 100.2 100.6 1.38 0.87
MP 50 100.0 99.53 0.29 1.33
100 100.0 101.1 0.41 1.41
120 100.3 99.93 0.59 1.14
PP 50 99.99 100.1 0.30 0.52
100 99.86 100.6 0.48 0.92
120 100.0 100.3 0.38 0.82
Nominal
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Table 3. Stability of standard and sample solutions in the autosampler at 25°C for 24 h
 RSD (%) of repetitive injections (n = 7)
Solutions  Peak area            Retention time
CIS MP PP CIS MP PP CIS MP PP
Standard solution -0.70 0.54 0.05 0.51 0.32 0.61 0.23 0.43 0.34
Sample solution of freshly prepared suspension 0.53 -0.79 -1.18 0.62 0.50 0.52 0.27 0.17 0.28
Sample solution of degraded suspension 0.57 -1.03 0.42 0.55 0.62 0.37 0.19 0.17 0.42
Change in peak area
(%) at 24 h
solutions, were stable in autosampler at 25°C for at least 24 h.
No significant changes in retention time, peak area and peak
purity were observed.
3.3 Application of the validated method
The  validated  method  was  applied  to  the  simulta-
neous determination of CIS, MP and PP in oral suspensions
with and without 3% w/v HP--CD in the stability study.
Representative chromatograms of freshly prepared suspen-
sion and degraded suspension are shown in Figure 2B and
2C, respectively. The changes in the amount of CIS, MP and
PP over time in the above mentioned oral suspensions at 5°C
and 30°C are shown in Figure 3. Stability was assessed based
on the 90% of drug remaining. The results demonstrated that,
when stored at 5°C CIS, MP and PP in oral suspension with
and without 3% w/v HP--CD were stable for at least 12.5
months. When stored at 30°C, HP--CD at this concentra-
tion increased the stability of MP and PP, but decreased the
stability of CIS as compared to the oral suspension formula-
tion  without  HP--CD.  At  30°C,  CIS,  MP,  and  PP  in  oral
suspension containing 3% w/v HP--CD were stable for at
least 160 days, 60 days, and 360 days, respectively.
4. Conclusion
The  developed  simultaneous  stability-indicating
HPLC method for determination of CIS, MP and PP in oral
suspension is selective, accurate and precise. The chromato-
graphic system provided chromatograms with good peak
shape and acceptable resolution of all analytes including the
degradation products formed in oral suspension in about 8.5
min. It was successfully applied in the stability study of CIS,
MP and PP in oral suspension formulations.
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Figure 3. % Remaining of CIS (A), MP (B) and PP (C) over time in
two  formulations  of  1  mg/mL  CIS  oral  suspension;
formulation without HP--CD at 5°C () and at 30°C
() and formulation with 3% w/v HP--CD at 5°C ()
and at 30°C ().
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